GET DAILY SIGNALSVera Therapeutics (VERA) Reports First Product Revenue After TRUTAKNA Launch
Key Takeaways
- Vera Therapeutics generated its first net product revenue of $10.3 million in the third quarter of 2026, fueled by the launch of TRUTAKNA following FDA accelerated approval in July 2026.
- The company recorded a net loss of $93.7 million, or $1.30 per share, which came in ahead of the consensus estimate of roughly -$1.61 to -$1.62 per share.
- Around 700 Patient Start Forms (PSFs) have been received since launch, pointing to early commercial traction in IgA nephropathy (IgAN).
- Research and development (R&D) spending decreased to $41.3 million from $56.5 million a year ago, while selling, general and administrative (SG&A) expenses increased sharply to support the commercial rollout.
- Vera finished the quarter with $384.0 million in cash, cash equivalents, and marketable securities, and filed a supplemental Biologics License Application (sBLA) for full approval of TRUTAKNA.
- For additional details on Vera Therapeutics' Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated pages.
- To find AI-driven trading ideas across the market, explore the Trending AI Robots.
Why This Quarter Stands Out
Vera Therapeutics' third-quarter 2026 results represent a clear shift from a clinical-stage biotech to a commercial-stage company. Following the FDA's accelerated approval of TRUTAKNA (atacicept-vymj) on July 7, 2026, the firm began recording product revenue for the first time. This period serves as an early indicator of launch execution, payer response, and physician uptake in IgA nephropathy, a condition affecting approximately 160,000 diagnosed patients in the U.S. From what I see, the focus now is on whether initial demand builds into consistent revenue growth and whether costs stay in check as commercial operations expand.
The Reported Figures
For the quarter ended September 30, 2026, Vera Therapeutics posted net product revenue of $10.3 million, up from zero in the same period last year and above consensus estimates of roughly $3.4 million to $3.78 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The net loss came in at $93.7 million, or $1.30 per share, compared with a net loss of $80.3 million, or $1.26 per share, a year earlier. The per-share result beat analyst expectations of about -$1.61 to -$1.62, helped in part by a higher share count after recent financings.
R&D expenses fell to $41.3 million from $56.5 million, with some manufacturing costs now classified as inventory post-approval. SG&A expenses rose to $61.4 million from $27.5 million to support the launch. Cash, cash equivalents, and marketable securities stood at $384.0 million, down from $714.6 million at the end of 2025.
Market Response and Sentiment
Shares of VERA declined roughly 5.7% in the session after the report, closing near $30.14. The move indicates that investors focused on the wider net loss and higher launch-related spending, even with the revenue beat and better-than-expected loss per share. Early signals look positive, with about 700 Patient Start Forms received, yet the market is waiting to see how quickly those convert into prescriptions and ongoing revenue. Upcoming regulatory milestones, including the full-approval review and planned European filing, will likely influence sentiment ahead.
Key Items to Follow Next
The main question going forward is whether TRUTAKNA's initial momentum can develop into steady, growing revenue. Tracking Patient Start Forms, payer coverage progress, and the conversion rate of new starts into reimbursed prescriptions will be essential.
On the regulatory side, Vera submitted its sBLA to the FDA on November 3, 2026, seeking full approval based on the ORIGIN 3 final efficacy data. Those results showed kidney function stabilization through 104 weeks, with an annualized eGFR slope of -0.6 mL/min/1.73m²/year for TRUTAKNA versus -5.6 mL/min/1.73m²/year for placebo.
The company also intends to file a Marketing Authorisation Application with the European Medicines Agency in the first quarter of 2027, potentially broadening the market beyond the current U.S. label.
Cost management remains important. While R&D declined this quarter, SG&A rose as the commercial team was built out. With roughly $384 million in cash plus $75 million drawn from its debt facility in late October, the firm has solid runway, though the balance between launch investment and losses will stay under scrutiny. These points are based on reported data and are not investment advice.
Using AI Tools in My Analysis
When evaluating names like VERA, I sometimes rely on Tickeron’s AI Screener to quickly filter peers and spot patterns across the sector. It helps streamline the process of comparing fundamentals and technical signals without manual effort. If you are looking to add similar capabilities to your own research, it is a practical option worth exploring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VERA's RSI Indicator ascends from oversold territory
The RSI Oscillator for VERA moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 26 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on VERA as a result. In 82 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for VERA just turned positive on October 20, 2026. Looking at past instances where VERA's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +5.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where VERA advanced for three days, in 238 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VERA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 54 cases where VERA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
VERA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VERA crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VERA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for VERA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. VERA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.327) is normal, around the industry mean (2.788). P/E Ratio (-5.135) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement